This report assesses racial disparities in the quality of inpatient care using 11 patient safety indicators that measure rates of adverse patient safety events of hospital-acquired illnesses or injuries.
This commentary explains how increased flexibility in the delivery and payment of telehealth across many coverage programs, but particularly in Medicaid and CHIP, throughout the COVID-19 pandemic has been a significant shift for some states. Many state officials are considering if and how to adapt rapidly implemented telehealth policies as the nation emerges from the public health emergency.
This commentary explains how since March 2020, many states have rapidly leveraged federal and state flexibilities under the public health emergency to expand telehealth capabilities and reimbursement through both public and private payers.
This commentary examines how Washington implemented the nation’s first public option for the 2021 plan year and in the first six months of 2021, states made significant progress in advancing public option proposals, with public option legislation advancing in Colorado, Nevada, and Oregon.
This commentary explains the federal government’s goal of reducing new HIV infections by 90% by 2030, the CDC has identified two policy strategies that states can employ for HIV prevention – provision of Pre-Exposure Prophylaxis medication and availability of Syringe Service/Exchange Programs.
This commentary analyzes how the U.S. Departments of Health & Human Services and Treasury have released a proposed rule governing the Affordable Care Act health insurance marketplaces and insurance standards for the plan year 2022.
This commentary explains how rising health care costs and increased consolidation of hospitals and provider groups into large health systems have led states into exploring ways to contain costs and provide oversight of the growing market power of large hospitals.
This commentary examines how recent approval of the Alzheimer’s drug Aduhelm under the U.S. Food & Drug Administration’s Accelerated Approval Program is controversial for a range of reasons, including its projected impact on state Medicaid budgets which will be required to cover the drug, priced at $56,000 a year, despite inconclusive evidence of its clinical effectiveness.
This chart details the amounts and required oversight of COVID-19 federal funds allocated to hospitals, providers, and states by the Families First Coronavirus Response Act (Families First Act), the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), the Paycheck Protection Program and Health Care Enhancement Act (HR 266), the Consolidated Appropriations Act, 2021, and the American Rescue Plan Act of 2021.